Abstract NG06: CHD1-loss confers AR targeted therapy resistance via promoting cancer heterogeneity and lineage plasticity
Zhang Z, Zhou C, Li X, Barnes S, Deng S, Hoover E, Chen C, Lee Y, Wang C, Tirado C, Metang L, Johnson N, Wongvipat J, Navrazhina K, Cao Z, Abida W, Lujambio A, Li S, Malladi V, Sawyers C, Mu P. Abstract NG06: CHD1-loss confers AR targeted therapy resistance via promoting cancer heterogeneity and lineage plasticity. Cancer Research 2020, 80: ng06-ng06. DOI: 10.1158/1538-7445.am2020-ng06.Peer-Reviewed Original ResearchMetastatic prostate cancerLineage plasticityAndrogen receptorResistance to ARShort hairpin RNAEpithelial to mesenchymal transitionChromodomain helicase DNA-binding protein 1Genomic alterationsCHD1 lossCancer heterogeneityProstate cancerClinical successTumor cellsLuminal prostate epithelial cellsProstate cancer cell line modelsWeeks of xenograftingTargetable driver mutationsCancer cell line modelsResistance to enzalutamideAR target genesProstate epithelial cellsProstate tumor cellsHuman prostate cancerProstate cancer heterogeneityAmerican Association for Cancer Research